about
Clinical implementation of a new electronic brachytherapy system for skin brachytherapyIn silico modelling of treatment-induced tumour cell kill: developments and advancesMorbidity related to axillary irradiation in the treatment of breast cancer.Development of clinical radiotherapy since 1896.Endocrine sequelae of cancer therapy in childhood.Growth and hormonal status of children treated for acute lymphoblastic leukaemia.Time factor for acute tissue reactions following fractionated irradiation: a balance between repopulation and enhanced radiosensitivity.Cancer and radiation therapy: current advances and future directions.Safety Profile of Amnion-Derived Cellular Cytokine Solution (ACCS) Following Topical Skin Application in Patients Receiving Breast Radiotherapy.Experimental radiation-induced heart disease. I. Light microscopic studies.Late effects of radiotherapy in the treatment of breast cancer.The Cancer Research Campaign (King's/Cambridge) trial for early breast cancer: an analysis of the radiotherapy data.Review: total doses in fractionated radiotherapy--implications of new radiobiological data.The Impact of Radiotherapy Dose on Local Control of Ewing's Sarcoma of Bone.Radiation myelopathyA Comparative Study of Daily 3-Gy Hypofractionated and 1.8-Gy Conventional Breast Irradiation in Early-Stage Breast CancerThe role of medical physicists and the AAPM in the development of treatment planning and optimization.Milestones in normal tissue radiation biology over the past 50 years: from clonogenic cell survival to cytokine networks and back to stem cell recovery.Radiation necrosis: relevance with respect to treatment of primary and secondary brain tumors.Future radiation therapy: photons, protons and particles.Tumor cell proliferation kinetics and tumor growth rate.The linear-quadratic formula and progress in fractionated radiotherapy.Biological effects and equivalent doses in radiotherapy: A software solutionTwo regimes with the same TDF but differing morbidity used in the treatment of stage III carcinoma of the cervix.Radiobiological aspects of fast neutron therapy.Carcinoma of the esophagus: surgery versus radiotherapy.Splenic irradiation in the palliation of patients with lymphoproliferative and myeloproliferative disorders.En-bloc irradiation of tumours of the head and neck and their lymphatics. II. Early results and side effects.Neurologic complications after irradiation of malignant tumors of the testis.Dose distribution in 42 MV roentgen irradiation of cervical carcinoma.Repopulation in human tumors. A biological background for fractionation in radiotherapy.Cell kinetics and radiation biology.The kinetics of tumour cell proliferation and radiotherapy.Postoperative radiotherapy in DBCG during 30 years. Techniques, indications and clinical radiobiological experience.The first James Kirk memorial lecture. What next in fractionated radiotherapy?Radiation physiology - evidence for a higher biological effect of 24 Gy in four fractions as compared to three.Radiotherapy of liposarcomas.Growth following therapy for childhood cancer.Radiosensitization by misonidazole (Ro-07-0582) of fractionated X-rays in a murine tumour.The relationship between o.e.r., r.b.e. and number of fractions for X-ray- or neutron-induced skin damage.
P2860
Q26865336-2D2087CD-5EF4-49EB-B247-DD9CFABA28ACQ27011493-A5AB792B-6212-406A-AD26-5B1B5494F9BCQ34033298-426D4F39-8E38-4309-8B60-4FCD7CA9087AQ34376122-3136C6F5-D25C-4C8A-8A46-90A8234C2681Q34444303-D99B3E12-A409-4C9C-9C17-1B1946F1C126Q34987031-EE8C3839-621C-4000-BCF1-C1C4BB360958Q35552500-B0F15D9A-DE23-485E-8257-750EC989A06FQ35816527-6DE5B90E-5458-43D5-A2A9-56731EA17475Q35908320-A9B2E20B-84CA-4A69-A529-A6C5BE6B402EQ36078872-A808AC62-E493-4C97-9230-BC8696FDF426Q36286960-92503243-C506-44DD-B222-377BA51EA968Q36601299-1220494C-1A33-4E19-9CD6-ACB3E514CFDDQ36602055-8951591F-50E6-49CD-9659-A3C030ACBC66Q36639294-406DD995-9C59-49E8-AF30-541321128A7FQ36992661-7DDC21D5-F41C-4BAA-9B86-66EC50B3742FQ36993295-DEB0BEE5-95A7-4C34-A0D5-BDEE6BB2310AQ37345399-1819FEB8-7DB2-4832-AE88-152D873DC41DQ37532183-59FEAD63-0174-48C1-AAF4-3CC98D0D8783Q37986496-067C36E1-50B4-4C50-9625-59983E612A30Q38096409-B13C0477-F023-44E0-B3AD-D7176BA14CB6Q38617591-57B55469-11FC-4D17-AA24-2FD425E23D37Q38678064-28804F65-4E3E-47FB-B19C-486FFC9B2D2EQ39174740-BF2BCDEA-A83A-4B4E-9AD5-9EDEF3401481Q39241842-BB140748-3D43-454F-9C33-1CD4B698146DQ39390521-1F80766B-815F-43C2-8CEA-7A670C50978FQ39420372-4CBC5C68-A6E8-4300-8DF8-FFE5EB196B22Q39461192-240D814C-0205-42BF-BB47-B63F2092F26EQ39621521-F4755C5C-30D5-4ADF-8946-CA1B1D062B12Q39637591-3BD09B11-BFE4-4C97-B874-DF63FD55CEB8Q39637601-4CD024CC-31CF-428A-B8A4-ED6E2678709FQ39650662-EE5E4286-6FDF-4AE3-A539-9EC59BDF27CEQ39726699-1E6F9E07-E101-4280-9C2F-6FAE39EE7F20Q39999363-C5D02F61-A5E9-4013-97D6-D5BA675C837EQ40094272-1AAE8234-2956-48B1-872A-0C08472A0419Q40169933-08CEB2FC-2143-4D3C-AA59-3821E08DD61FQ40256868-A4464749-98BE-493F-B59E-E3CAE6E015B6Q40364596-F1CB8C08-9F59-47EB-BC8F-FEAFBB19D999Q40409865-84E36FE3-F909-49D4-A1AA-84844D4A45EEQ40544521-66E7E948-B2C6-4C81-9E3F-87F17C0101A1Q40726047-34E73BDD-EF0A-4BE4-A476-8811B917FA75
P2860
description
1969 nî lūn-bûn
@nan
1969年の論文
@ja
1969年論文
@yue
1969年論文
@zh-hant
1969年論文
@zh-hk
1969年論文
@zh-mo
1969年論文
@zh-tw
1969年论文
@wuu
1969年论文
@zh
1969年论文
@zh-cn
name
Dose, time and fractionation: a clinical hypothesis.
@en
type
label
Dose, time and fractionation: a clinical hypothesis.
@en
prefLabel
Dose, time and fractionation: a clinical hypothesis.
@en
P1433
P1476
Dose, time and fractionation: a clinical hypothesis.
@en
P2093
P356
10.1016/S0009-9260(69)80043-7
P577
1969-01-01T00:00:00Z